| Literature DB >> 31958132 |
Gena Huang1,2,3,4, Chen Song2, Ning Wang1,3,4, Tao Qin5, Silei Sui6, Alison Obr7, Li Zeng1,3, Teresa L Wood7, Derek Leroith8, Man Li2, Yingjie Wu1,3,4,8,9.
Abstract
The insulin receptor gene (INSR) undergoes alternative splicing to give rise to two functionally related, but also distinct, isoforms IR-A and IR-B, which dictate proliferative and metabolic regulations, respectively. Previous studies identified the RNA-binding protein CUGBP1 as a key regulator of INSR splicing. In this study, we show that the differential splicing of INSR occurs more frequently in breast cancer than in non-tumor breast tissues. In breast cancer cell lines, the IR-A:IR-B ratio varies in different molecular subtypes, knockdown or overexpression of CUGBP1 gene in breast cancer cells altered IR-A:IR-B ratio through modulation of IR-A expression, thereby reversed or enhanced the insulin-induced oncogenic behavior of breast cancer cells, respectively. Our data revealed the predominant mitogenic role of IR-A isoform in breast cancer and depicted a novel interplay between INSR and CUGBP1, implicating CUGBP1 and IR-A isoform as the potential therapeutic targets and biomarkers for breast cancer.Entities:
Mesh:
Substances:
Year: 2020 PMID: 31958132 PMCID: PMC7513956 DOI: 10.1093/carcin/bgz141
Source DB: PubMed Journal: Carcinogenesis ISSN: 0143-3334 Impact factor: 4.944